Investing to become financially independent
Investing to become financially independent
Find out why Roche shares, listed on the Zurich Stock Exchange under the symbol ROG, are still an attractive choice despite their high valuation. An in-depth analysis of the financial fundamentals after the health crisis and the promising outlook for shareholders.
Roche, the world's leading cancer drug company, is trading at a high valuation relative to its fundamentals, raising questions about its true potential. While its results are impressive, the question remains: does this high-quality company deserve such a price in the market?
The transition from Boomer to Generation X to Generation Y is shaping our society and influencing today’s financial markets. Learn how a diversified investment portfolio can capitalize on the unique needs of each generation, including in the retail, consumer goods, and technology sectors.
Generations & investment (7/7): consequences & conclusion Read More »
A common mistake investors make is to focus solely on high dividend yields, ignoring the potential risks of dividend cuts or elimination. Find out why it makes more sense to focus on companies like Novo Nordisk, IBM and Roche, which offer sustainable and consistent dividend growth rather than just high yields.
Stan Weinstein warns us against buying stocks in a bear market, but sometimes exceptional circumstances require us to deviate from the traditional rules. In a turbulent market context, it may be wise to prepare for one of the biggest bull markets in history, while keeping an eye on key indicators such as the Dow Gold ratio.
Discover Roche, the Swiss pharmaceutical giant, world leader in cancer treatment and virology, with flagship products such as Valium and Tamiflu. The group offers an attractive yield of 3.24% and a sustained growth of its dividends, making it an interesting investment despite a higher volatility than its competitors.
Français